Phase A — Understand the business
Lens 1 · Company Overview
Innoviz is an Israeli (Rosh HaAyin) Tier-1 direct supplier of automotive-grade LiDAR sensors plus a complementary perception software stack. Incorporated January 2016; went public April 2021 via SPAC merger with Collective Growth (Perception Capital / Antara), raising ~$370M in gross proceeds.
Business model — two revenue lines, and the mix is the whole story:
- NRE (non-recurring engineering) — paid development work for OEM programs, recognized at milestones/customer-acceptance. This is the dominant line today: NRE contributed ~$37.2M of FY25's $55.1M revenue, vs ~$18.0M of FY24's $24.3M.
- LiDAR sensor product sales — recognized point-in-time on delivery. Still small; the volume ramp is ahead, not behind.
FY25 revenue was further flattered by a one-time $8.4M sale of machinery to a customer — i.e. ~$45.6M of the $55.1M is NRE + a non-recurring machinery sale, and recurring product revenue is modest.
Architecture: direct-detection Time-of-Flight (ToF) at ~905nm wavelength, using mature silicon detectors — deliberately chosen over 1550nm (more expensive InGaAs, more power, larger form factor) and over FMCW (which Innoviz argues is less automotive-mature). They own a custom signal-processing ASIC. Product ladder: InnovizOne → InnovizTwo (Long-Range + Short-to-Mid) → InnovizThree (3rd-gen, announced Dec 2025, CES Jan 2026, engineering samples only) → InnovizSMART/SMARTer for non-automotive.
Customers / programs (the crown jewels): BMW L3 (first design win 2018, reached series maturity 2024); Volkswagen (direct supplier across several brands incl. ID.Buzz, InnovizTwo); Mobileye (InnovizTwo LR + SMR for Mobileye Drive); Daimler Truck (Sept 2025, future series supplier for SAE L4 Class-8 trucks). A concrete near-term deployment: MOIA's VW ID.Buzz robotaxi on the Uber platform in Los Angeles by YE2026 — 9 InnovizTwo LiDARs per vehicle (3 LR + 6 SMR). Contract structure is automotive design-win economics: long, expensive qualification cycles, then (theoretically) multi-year series-production volume — but with no take-or-pay protection disclosed, and revenue from each win is admittedly hard to predict.
Lens 2 · Supply Chain
Upstream → Innoviz → end customer, named where disclosed:
- Inputs: ~905nm laser diodes, silicon photodetectors (the cost-advantage vs InGaAs), a proprietary in-house signal-processing ASIC, MEMS/scanning optics, and IC packaging. Components are sourced "from a variety of third-party manufacturers"; Innoviz designs critical components in-house rather than buying off-the-shelf modules. Specific upstream chip/laser vendors are n/a — not named in the 20-F.
- Manufacturing: InnovizTwo is built at Innoviz HQ and at contract manufacturers with automotive-grade facilities. The named CM is Fabrinet — the Q1 2026 ramp shipped "a record number of units… about half of what we shipped in all of 2025" in a single quarter. InnovizThree samples are still built in-house.
- Downstream: sells direct to OEMs as Tier-1 (VW, Daimler Truck) and through Tier-1 partners as Tier-2 (e.g. via Mobileye's Drive platform; Torque on the Daimler program). Non-automotive goes through channel partners (security/perimeter — Kela for drone detection; LOXO LOI for L4 delivery).
Chokepoints / single-source risk: the in-house ASIC is both a moat and a single point of dependency. Management states it currently holds "sufficient component inventory" for near-term demand and is building buffer stock. The deeper chokepoint is demand-side, not supply-side: the entire chain is gated on OEM SOP timing, which Innoviz does not control.
Lens 3 · Competitive Advantages (moats)
What's genuinely defensible:
- Automotive-grade certification stack — ISO 26262 (functional safety), IATF 16949, ISO/SAE 21434 (cybersecurity), ASPICE CL1, ISO 17025, ISO 27001. These take years and are a real barrier to new entrants — a credentialing moat more than a technology moat.
- Marquee design wins as proof-of-trust — BMW/VW/Mobileye/Daimler Truck. In automotive, a competitor cannot simply price you out of a won socket mid-program; switching costs within a program are high.
- IP — 81 issued patents + 124 pending as of 2025-12-31, across systems, lasers, scanners, receivers, optics, perception.
- Cost architecture — the 905nm/silicon/ToF choice is a structurally cheaper BOM than 1550nm rivals; each generation has cut cost.
Where the moat is thin (be honest):
- Bargaining power is inverted. Innoviz's own risk factors concede it targets "large companies with substantial negotiating power, exacting product standards and potentially competitive internal solutions". A ~$130M-market-cap supplier negotiating against VW/Mobileye is the weaker party.
- The market leader is pulling away. Hesai shipped its 1,000,000th LiDAR in 2025 and is doubling capacity toward 4M units; it holds ~55% of China long-range auto LiDAR. Scale economics in this industry accrue to the volume leader — and that is not Innoviz.
- No network effects; software stack is real but not a lock-in flywheel yet.
Lens 4 · Segments
Innoviz does not report multiple operating segments — it runs as a single reportable segment, disaggregated only by revenue type (LiDAR products + NRE) and not by product line or geography in the 20-F segment note. segments.csv was empty. What can be sourced:
- By revenue type (FY25): NRE ~$37.2M, machinery sale ~$8.4M, LiDAR sensor sales = the residual ~$9.5M.
- By end-market trajectory: automotive is ~99% of FY25 revenue; non-automotive is guided to rise from ~1% of revenue in 2025 to up to ~10% in 2026 — a deliberate pivot toward shorter-cycle, higher-ASP "Physical AI" applications (security, infrastructure, robotics, aerial) to bridge revenue while auto SOPs slip.
- By geography: substantially all revenue is USD-denominated; cost base is heavily ILS (Israel) — the USD devalued ~12.5% vs ILS in 2025, inflating the USD cost of operations.
Trend read: revenue type mix is the risk. A P&L that is ~83% NRE + one-off machinery is not yet a product company — it is a funded engineering shop whose product ramp is still a forward promise.
Phase B — Measure performance
Lens 5 · Earnings Result
FY2025 (audited, 20-F):
| Metric | FY2025 | FY2024 | Δ |
|---|
| Revenue | $55.089M | $24.268M | +127% |
| Gross profit | $12.905M | $(1.161)M | turned positive |
| Gross margin | 23% | (5)% | +28pp |
| R&D | $56.478M | $73.817M | −23% |
| Total opex | $80.638M | $100.757M | −20% |
| Operating loss | $(67.733)M | $(101.918)M | improved |
| Net loss | $(67.795)M | $(94.757)M | improved |
| EPS (basic/diluted) | $(0.34) | $(0.57) | — |
| Wtd-avg shares | 199.9M | 167.2M | +20% |
On paper FY25 looked like a turnaround: revenue +127%, first-ever positive gross margin, opex down 20%. But the quality is poor — the revenue beat was NRE + a one-time machinery sale, the gross-margin flip was partly from "decreased production inefficiencies of InnovizOne and decreased excess & obsolete inventory" (i.e. fewer write-offs, not operating leverage), and the opex drop was a 23% R&D cut driven by headcount reduction and lower SBC, not efficiency. Cutting R&D 23% at a company whose entire thesis is staying technically ahead is a runway-preservation move, not strength.
Then the print that matters — Q1 2026 (post-20-F):
- Revenue $7.1M, down from $17.4M in Q1 2025 — NRE milestones "pushed into coming quarters… in part due to customers' requests for additional content."
- Gross margin ~ −22% (back negative — low fixed-cost absorption on low unit volume).
- Net loss $26.2M (vs $12.6M Q1 2025); opex $24.9M (+18% YoY).
- Liquidity ~$60.1M, no long-term debt; ~$15.8M quarterly cash + capex use.
- Management reaffirmed FY26 revenue guide of $67–73M (~27% growth at midpoint) and 2–3 new programs.
This is the central tension: full-year guidance held while Q1 came in at ~10% of the annual midpoint, implying a very back-half-loaded year. Hitting $67–73M now requires ~$60M+ across the remaining three quarters.
Balance-sheet flags: cash fell from $72.1M (YE25) to $60.1M (Q1 26) — one quarter consumed ~$12M of liquidity. At that pace the disclosed "sufficient for at least 12 months" runway is real but finite, and the ATM is the safety valve.
Lens 6 · Earnings Calls (sentiment trend)
transcripts/ was empty; sourced from web. Tone over the last several quarters has been persistently, structurally optimistic regardless of results — "robust pipeline," "executing on the plan," "renewed momentum in lidar / Physical AI". The recurring phrases: design wins, NRE, SOP (start of production), Physical AI, Fabrinet ramp. What's notably absent from management's voice: any direct address of the sub-$1 share price, the Nasdaq deficiency, a reverse split, or dilution — the Q1 2026 call did not engage them. The sentiment delta over time is subtle: the story (Physical AI, multi-program ramp) has gotten bigger while the near-term numbers have gotten worse — a widening gap between narrative and tape that the market has clearly chosen to price on the tape.
Lens 7 · Comps
Western/Asian LiDAR peer set. Multiples are `` with date or n/a.
| Company | Ticker | Mkt cap | Latest qtr rev (YoY) | Profitable? | EV/Sales | Note |
|---|
| Hesai | HSAI | ~$3.46B | $99M Q1'26 (+30%) | Yes — GAAP profitable 4 qtrs | n/a | Volume + scale leader; ~471k units/qtr; Mercedes L3 win |
| Aeva | AEVA | ~$1.70B | $6.3M Q1'26 (+90%) | No (−$25.8M op loss/qtr) | n/a | FMCW; FY26 rev guide $33M |
| Ouster | OUST | ~$1.3B | — (+30% FY est) | No | n/a | Diversified beyond auto |
| Innoviz | INVZ | ~$130–161M | $7.1M Q1'26 (−59%) | No | n/a | TTM rev ~$55M; −123% net margin |
| Luminar | LAZR | ~$0.05B (post-restructuring) | — | No | n/a | Near-wipeout; founder legal issues |
The comp read is brutal and clarifying. On TTM revenue (~$55M) Innoviz is roughly mid-pack among Western names, yet its market cap (~$130–161M) is ~5% of Hesai's and ~8–9% of Aeva's despite Aeva having a fraction of Innoviz's revenue. The market is not paying Innoviz an LiDAR-peer multiple — it is pricing in dilution + delisting risk. The two opposite poles (Hesai = profitable scale; Luminar = near-zero) frame the binary outcome space Innoviz sits between.
Lens 8 · Stock-Price Catalysts
Pattern over the last ~2 years:
- Down −47% over the trailing 12 months; −25% in one recent 30-day window.
- March 26, 2025: first Nasdaq sub-$1 deficiency notice (Rule 5450(a)(1)).
- 2025 (mid-year): "optimization of operations" — ~9% headcount cut, ~$12M 2025 cost savings, framed as runway extension.
- Goldman Sachs downgrade to Neutral, PT cut to $0.75 (from $1.25).
- March 25, 2026: second formal Nasdaq notice (Rule 5550(a)(2)), 180-day grace to Sept 21, 2026.
- Institutional ownership reportedly collapsed ~66% as funds exit ahead of the delisting clock.
- May 14, 2026: Q1 2026 miss (revenue $7.1M).
What moves this stock: not earnings beats — it reacts to (a) financing/dilution events, (b) the listing clock, and (c) headline design-win announcements. The market treats design wins as call-option premium and treats every quarter of cash burn as theta decay. This is a survival-and-dilution name, not a fundamentals-compounding name — yet.
Phase C — Judge people & books
Lens 9 · Management
- CEO Omer Keilaf (46), co-founder, in seat since 2016. Ex-STMicroelectronics, Consumer Physics, IDF elite intel/tech unit; BSc/MSc EE + MBA, Tel Aviv University. Track record: the genuinely impressive achievement is landing BMW's L3 series-production design win in 2018 as a startup, beating older incumbents. Founder-operator archetype, deeply technical.
- CFO Eldar Cegla (since 2017); CR&DO Avishay Moscovici (ex-Motorola/Freescale/NXP); long-tenured insiders — low executive churn, which for a long-cycle automotive supplier is a positive.
- Board pedigree is unusually strong for a microcap: Chairman Amichai Steimberg (ex-CEO Orbotech, acquired by KLA); Stefan Jacoby (ex-CEO Volvo Cars, ex-CEO VW Group of America — directly relevant automotive credibility); Aharon Aharon (ex-CEO Israel Innovation Authority, ex-GM Apple Israel); Dan Falk (NICE, Evogene boards).
- Skin in the game: insiders + directors as a group hold 5.2% (CEO 2.3%, incl. options/RSUs vesting in 60 days). Real but modest; not a high-conviction founder stake.
- Capital-allocation history — the weak spot. Burned through most of the
$370M SPAC war chest; diluted from 169.4M → 214.1M shares in 2025 alone (~25%) via a Feb 2025 registered direct ($37.3M), an August 2025 Jefferies ATM (~$13.3M of a $75M facility used), and option exercises. ROE/ROIC are deeply negative (sustained operating losses). To their credit, the FY25 opex discipline (−20%) and the Tier-1 strategic pivot were sound calls. Red flags: in December 2025 the board granted CEO Keilaf 6,256,265 PSUs plus the group's existing 3.78M options (WAEP $7.45) and 9.44M RSUs — a very large equity grant as the stock collapsed toward $0.60, which optically rewards the team during a drawdown even if vesting is share-price-performance-gated. Total FY25 named-exec comp ~$5.1M; CEO ~$1.29M (~62% equity).
- Founder vs professional: clearly founder-led. At this stage that cuts both ways — conviction and technical depth, but also the optimism bias visible on the calls.
Lens 10 · Forensic Red Flags
Acting as a forensic analyst on the 20-F:
- Revenue recognition / quality (highest-priority flag). Revenue is ~83% NRE + a one-off $8.4M machinery sale. NRE is milestone/acceptance-based — inherently lumpy and partly discretionary in timing, which Q1 2026 proved when milestones "pushed out" and revenue fell 59% YoY. The "127% growth" headline is low-quality. The $8.4M machinery sale is non-recurring and should be stripped from any run-rate.
- Cash vs earnings. Operating cash use ($47.9M) was less than net loss ($67.8M) — but the bridge is $16.0M SBC + $5.9M D&A, i.e. losses are flattered by heavy non-cash stock comp, not by genuine cash generation.
- SBC is large relative to the P&L: $16.0M SBC in FY25 (down from $19.7M) on a company this size, and the ongoing 5%/yr evergreen share-reserve increase + Jan 2026 +16.96M-share reserve top-up institutionalize dilution.
- FX exposure: USD revenue / ILS cost base; a swing of the ~$5.0M FX line wiped out nearly all "financial income, net" (FY25 $0.1M vs FY24 $7.3M).
- Going concern: No going-concern qualification. Management explicitly states liquidity (~$72.1M YE25) is "sufficient… for at least the next 12 months". No "substantial doubt" language appears in the filing. This is the reassuring counter to the bear case — bankruptcy is not the near-term risk; dilution and delisting are.
- Remaining performance obligations: only ~$7.6M of contracted RPO to recognize within 12 months — a thin contracted backlog relative to a $67–73M guide, underscoring how much of FY26 is not yet under contract.
Regulatory findings sub-section:
- SEC Litigation Releases: none naming Innoviz (EDGAR EFTS LR, 2021-06-18→2026-06-18).
- SEC AAERs: none.
- Item 3 / Legal Proceedings (company's own disclosure): "not currently a party to any material… legal proceedings". The one disclosed matter is the Sheadrick Richards lawsuit (filed March 28, 2024) — a purported Collective Growth stockholder alleging the SPAC's 2021 business-combination disclosures were "materially incomplete and misleading" and that directors breached fiduciary duties. Innoviz indemnifies certain former Collective Growth directors/officers; it carries run-off insurance but warns coverage "may not cover all claims". This is legacy-SPAC litigation, not an operating-fraud signal.
- Non-SEC web search ("Innoviz" + FTC/DOJ/FDA/CFPB/consent decree/settlement/penalty): no material enforcement hits found.
- Net: No material regulatory or accounting-enforcement findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 20-F Item 3/Item 8 as of 2026-06-18. The accounting risk is revenue-quality/dilution, not fraud.
Phase D — Project & stress-test
Lens 11 · Forward Projection
Bottom-up from FY25 actuals + the reaffirmed FY26 guide. All ``, inputs labelled. EPS will stay deeply negative across the projection window — the relevant variable is not EPS but revenue trajectory, cash burn, and share count.
- FY2026 (current year): revenue $67–73M per reaffirmed guidance — but with Q1 at $7.1M, this is steeply back-half-loaded and carries high miss risk. NRE $20–30M of new payments; non-auto to
10% of revenue. Assume opex roughly flat-to-up ($95–100M run-rate from Q1's $24.9M ×~4) → operating loss ~$(60)–(75)M. Net loss EPS ≈ $(0.40)–(0.50) on ~220–235M wtd shares.
- FY2027: if VW/Mobileye/MOIA SOP volume genuinely ramps, revenue could step to ~$90–120M; but equally a program slip leaves it ~$70–80M. Operating loss narrows only if product (not NRE) gross margin scales. EPS ≈ $(0.25)–(0.40), share count likely +5–15% from continued ATM use.
- FY2028: the year management points to ("numerous L2+/L3/L4 programs decided in 2026, SOP 2028+"). Bull path: revenue $150M+ with positive product gross margin and a path toward operating breakeven; bear path: still sub-$100M and out of independent runway, having done a reverse split. EPS still likely negative.
Runway-to-catalyst (the lens that actually matters here): ~$60.1M liquidity (Q1'26) ÷ ~$50–55M annual cash burn ≈ ~12–14 months of independent runway, extendable via the ~$60M of unused ATM capacity. The cash question and the Nasdaq Sept-21-2026 listing clock converge in H2 2026. Forecast NOT logged (forecast.ts create skipped per --watchlist rules). The scoreable binary I would track: "INVZ reports FY2026 revenue ≥ $67M (low end of guide)" — my subjective p ≈ 0.30 given the Q1 hole.
Lens 12 · Bull vs Bear
Bull case. Innoviz is a real Tier-1 with certified, OEM-validated product and a design-win roster (BMW, VW, Mobileye, Daimler Truck) that competitors cannot quickly replicate — credentials that take years. The Physical-AI/LiDAR secular tailwind is intact and broadening (Mercedes/Hesai L3, NVIDIA Hyperion). Concrete 2026 deployments (MOIA/VW ID.Buzz robotaxi on Uber in LA, 9 sensors/vehicle) convert "design win" into shipped units; Fabrinet ramp is real (1 quarter = half of all 2025 units). Non-auto going 1%→10% adds shorter-cycle revenue. At ~$130M market cap on ~$55M TTM revenue with marquee customers and no debt, the risk/reward is asymmetric IF SOP volume arrives — sell-side median PT ~$2.03 implies ~190% upside. The contrarian read: the market has fully priced delisting and is mispricing the option value of the won sockets.
Bear case (2–3 permanent-impairment risks).
- Dilution death-spiral + reverse split. Sub-$1, a Sept-21-2026 listing deadline, ~$50M/yr burn, and an active ATM = the most likely path is more shares at lower prices, then a reverse split that "signals desperation" and resets the option lower. Equity holders can be structurally impaired even if the business survives.
- Revenue is NRE-funded engineering, not product. ~83% NRE + one-off machinery in FY25, then a 59% revenue collapse the moment milestones slipped (Q1'26). If product SOP volume keeps slipping right (automotive's chronic habit), the company funds itself by issuing stock indefinitely.
- The leader is compounding away. Hesai is GAAP-profitable, shipping >1M units/yr, doubling to 4M, winning Mercedes L3 — scale economics flow to it, not to a sub-scale Israeli supplier whose R&D it just cut 23%.
Pre-mortem (18 months out, thesis broke): It's late 2027. Two of the "2026-decided" programs slipped to 2029 SOP; FY26 came in ~$55M (missed the guide); the company did a 1-for-10 reverse split in Q4 2026 to hold Nasdaq, raised dilutive equity twice more, and the stock is a post-split ~$3 that's already drifting back down. The product works — but volume never showed up fast enough to outrun the cash clock.
Are multiples too high? No — multiples are low (≈5% of Hesai's cap on comparable revenue). The bear case isn't "overvalued," it's "the equity is an option that may expire / be diluted before it pays."
Lens 13 · Devil's Advocate (short-seller)
Dismantling the bull case: The bull thesis rests entirely on future SOP volume the company does not control and has repeatedly failed to time. Revenue is concentrated in a handful of OEM programs (VW, Mobileye, Daimler Truck) — lose or slip any one and the model breaks; Q1 2026 showed a single quarter of milestone slippage halves revenue. The moat bulls cite (certifications, design wins) did not protect the stock from a −47% year because in automotive a "design win" is a multi-year option, not a contract — OEMs can de-scope, delay, or dual-source (note Innoviz's own disclosure that customers are "potentially competitive internal solutions"). The most dangerous competitor bulls underestimate is Hesai, whose profitability + 4M-unit capacity means it can win Western programs on price and scale while Innoviz is cutting R&D to survive. Worst capital-allocation tells: 25% dilution in a single year and a 6.26M-PSU CEO grant as the stock cratered. For today's ~$0.61 to hold, you must believe FY26 hits ~$70M (Q1 says ~$7M), the company avoids a punitive reverse split, and product margin inflects — three things that must all go right. If revenue disappoints 20–30% (i.e. lands ~$50–55M, flat-ish), the cash clock tightens, the ATM runs harder, and a reverse split becomes near-certain — permanently impairing per-share value even if enterprise value holds. The single scenario that permanently impairs: a program cancellation by VW or Mobileye, which would simultaneously gut revenue and the credibility that underwrites every other RFQ. Plausibility: moderate, not negligible.
Lens 14 · Management Questions (ordered by information value)
- Q1 2026 revenue was $7.1M against a reaffirmed $67–73M full-year guide — quarter by quarter, what specific NRE milestones and product shipments bridge the remaining ~$60M, and which are contracted vs forecast?
- With ~$60M liquidity, ~$50M annual burn, and a Sept-21-2026 Nasdaq deadline — what is your explicit plan to regain $1 compliance, and under what conditions would you execute a reverse split?
- How much of FY26 revenue is product (units shipped) vs NRE vs one-off, and when does product revenue exceed NRE for the first time?
- For VW, Mobileye, and Daimler Truck individually: what is the contracted SOP date, the committed annual unit volume, and the per-vehicle content — and what penalties or take-or-pay protect you if they slip?
- Of the ~$60M unused ATM capacity, how much do you expect to draw in 2026, and at what point does dilution become value-destructive enough to prefer strategic alternatives?
- You cut R&D 23% in 2025 — which programs were deprioritized, and how do you stay ahead of Hesai's scale while spending less?
- What is your realistic path to product gross margin >30%, and at what cumulative unit volume does fixed-cost absorption turn the corner?
- Hesai is GAAP-profitable at >1M units/yr and won Mercedes L3 — where do you win against it in Western programs, concretely, on something other than "we're automotive-grade too"?
- The Dec-2025 6.26M-PSU CEO grant: what are the exact share-price/performance hurdles, and how do you defend a grant of that size during a >40% drawdown?
- Non-auto is guided 1%→10% of revenue — is this a durable second leg or a bridge to fill the auto-SOP gap, and what are the ASPs/margins there?
- What would a strategic acquirer (a Tier-1 like Continental/Valeo, or an OEM) pay for the certified IP + design-win book, and is a sale a live alternative to standalone dilution?
- The Fabrinet ramp shipped half of 2025's units in Q1 2026 — what is installed annual capacity, and is it demand- or supply-constrained today?
- How exposed is the cost base to further USD/ILS moves, and do you intend to hedge beyond the current 3-month window?
- On the Sheadrick Richards (Collective Growth) litigation — what is the current status, your reserved/expected exposure, and insurance adequacy?
- If by mid-2027 the 2028-SOP programs have not converted to firm volume, what is Plan B?